Companies Astria Therapeutics
Astria Therapeutics (ATXS): executive pay, fiscal 2024
Free brief. Every figure links to the company’s own filing.
Velarion Intel: free for 3 days, no card →Email me Astria Therapeutics’s executive pay brief as a PDF
You get it on this page the moment you ask, and a copy by email. Every figure is cited to its filing.
After the PDF, up to three short notes on the deeper reports for this company. Reply “unsubscribe” to any of them, any time.
CEO vs. named peers80th pct.Of 17 peer CEOs
CEO pay, last three years
- $2,955,504FY2023
- $6,604,416FY2024
CEO total pay was $6,604,416 in fiscal 2024, up from $2,955,504 in fiscal 2023.
FY2024: salary $637,868 · bonus $0 · stock awards $0 · option awards $5,637,078
Executives and directors
Benjamin Harshbarger · General CounselJill Milne · CEOChristopher Morabito · Chief Medical OfficerFred Callori · Independent DirectorGregg Lapointe · Independent DirectorHugh Cole · Independent DirectorJoanne Beck · Independent DirectorJonathan Violin · Independent DirectorKenneth Bate · Chair of the BoardMichael Kishbauch · Independent DirectorSunil Agarwal · Independent Director
Frequently asked questions
Who was the highest-paid executive at Astria Therapeutics in fiscal 2024?
As disclosed, Jill Milne (President and Chief Executive Officer) was the highest-paid executive at Astria Therapeutics in fiscal 2024, with total compensation of $6,604,416.
How does Astria Therapeutics's chief executive pay compare to its disclosed peer group?
As disclosed, Jill Milne's total compensation ranked at the 80th percentile of Astria Therapeutics's disclosed peer group.
How did shareholders vote on Astria Therapeutics's executive compensation?
As disclosed, 86.82% of shareholders supported Astria Therapeutics's executive compensation in the latest say-on-pay vote.
How much does Astria Therapeutics spend in total on board compensation for fiscal 2024?
As disclosed, Astria Therapeutics reported total board compensation of $444,723 for fiscal 2024.
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Full detail
Every table from the filing. Open any section.
Summary compensation table
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Jill Milne | $637,868 | $0 | $0 | $5,637,078 | $318,934 | $0 | $10,536 | $6,604,416 |
| President and Chief Executive Officer | ||||||||
| Christopher Morabito | 485,920 | 0 | 0 | 1,789,892 | 194,368 | 0 | 10,536 | 2,480,716 |
| Chief Medical Officer | ||||||||
| Benjamin Harshbarger | 461,617 | 0 | 0 | 1,789,892 | 184,647 | 0 | 11,777 | 2,447,933 |
| Chief Legal Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
Three-year trend — total compensation per named executive
| Named executive officer | FY2024 total | FY2023 total | FY2022 total | Δ FY2023→2024 |
|---|---|---|---|---|
| Jill Milne | $6,604,416 | $2,955,504 | — | ↑ +3,648,912 |
| Christopher Morabito | 2,480,716 | 1,321,586 | — | ↑ +1,159,130 |
| Benjamin Harshbarger | 2,447,933 | 1,297,491 | — | ↑ +1,150,442 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Incentive-plan design — the Compensation Discussion & Analysis
We consider compensation for comparable positions in the market, historical compensation levels, individual performance, and our desire to motivate executives to achieve short- and long-term results in the best interests of stockholders. We do not target a specific mix of compensation among base salary, bonus, or equity incentives.
| CEO STI target (% of salary) | 50% |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Aon |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | true |
Equity grants and outstanding awards
No plan-based awards are on file for this fiscal year.
Outstanding equity awards at fiscal year-end 2024
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Benjamin Harshbarger | Option | 4,164 | 12.96 | — |
| Benjamin Harshbarger | Option | 5,556 | 17.22 | — |
| Benjamin Harshbarger | Option | 16,042 | 6.51 | — |
| Jill Milne | Option | 19,444 | 17.22 | — |
| Christopher Morabito | Option | 39,583 | 3.87 | — |
| Christopher Morabito | Option | 48,750 | 13.36 | — |
| Benjamin Harshbarger | Option | 48,750 | 13.36 | — |
| Jill Milne | Option | 56,875 | 6.51 | — |
| Jill Milne | Option | 148,958 | 13.36 | — |
| Christopher Morabito | Option | 175,000 | 15.26 | — |
| Benjamin Harshbarger | Option | 175,000 | 15.26 | — |
| Jill Milne | Option | 534,600 | 15.26 | — |
Director compensation
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Sunil AgarwalIndependent · Science and Technology | $34,973 | $0 | $221,309 | — | $0 | $256,282 |
| Kenneth BateIndependent · Board Chair · Audit | 90,500 | 0 | 86,980 | — | 0 | 177,480 |
| Gregg LapointeIndependent · Audit (Chair) | 60,000 | 0 | 86,980 | — | 0 | 146,980 |
| Jonathan ViolinIndependent · Science and Technology (Chair) | 55,000 | 0 | 86,980 | — | 0 | 141,980 |
| Michael KishbauchIndependent · Compensation (Chair) | 54,000 | 0 | 86,980 | — | 0 | 140,980 |
| Joanne BeckIndependent · Compensation · Science and Technology | 52,500 | 0 | 86,980 | — | 0 | 139,480 |
| Fred CalloriIndependent · Compensation | 49,000 | 0 | 86,980 | — | 0 | 135,980 |
| Hugh ColeIndependent · Audit · Compensation | 48,750 | 0 | 86,980 | — | 0 | 135,730 |
| Jill C. MilneEmployee director | 0 | 0 | 0 | — | 0 | 0 |
Board fee structure and ownership guideline
| Annual cash retainer | $40,000 |
|---|---|
| Annual equity retainer | — |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 20,000 / 10,000 / 8,000 |
| Stock ownership guideline | — |
Total cost of the board
| Component | FY2024 |
|---|---|
| Cash retainers and fees | $444,723 |
| Equity awards (grant-date value) | $0 |
| All other compensation | $0 |
| Total cost of the board | $444,723 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Peer group, and who names Astria Therapeutics as a peer
Companies that benchmark against ATXS
9 companies name ATXS as a compensation peer
- Altimmune, Inc.ALTFY2025
- ANAPTYSBIO, INCANABFY2025
- Dianthus Therapeutics, Inc. /DE/DNTHFY2025
- Jade Biosciences, Inc.JBIOFY2025
- NEKTAR THERAPEUTICSNKTRFY2025
- Oruka Therapeutics, Inc.ORKAFY2025
- Savara IncSVRAFY2025
- Spyre Therapeutics, Inc.SYREFY2025
- Trevi Therapeutics, Inc.TRVIFY2025
Each company listed discloses ATXS in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named ATXS in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.
Disclosed peer group — fiscal year 2024
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
FHTX Foghorn Therapeutics, Inc.LRMR Larimar Therapeutics, Inc.OCGN Ocugen, Inc.CUE Cue Biopharma, Inc.SVRA Savara, Inc.EWTX Edgewise Therapeutics, Inc.RLYB Rallybio Reneo Pharmaceuticals, Inc.THRD Third Harmonic BioHOWL Werewolf Therapeutics, Inc.VRDN Viridian Therapeutics, Inc.ACET Adicet Bio, Inc.INZY Inozyme Pharma, Inc.VIGL Vigil Neuroscience, Inc. Aerovate Therapeutics, Inc.ANNX Annexon Biosciences AVROBIO, Inc.
Peer reciprocity
The companies Astria Therapeutics names as compensation peers that name it back in their own disclosed peer groups.
Chief executive pay against the peer group
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Edgewise Therapeutics, Inc. | 2025 | Kevin Koch | $670,000 | $1,171,625 | $5,041,621 | $462,300 | $7,359,546 |
| 2 | Viridian Therapeutics, Inc. | 2025 | Stephen Mahoney | 700,000 | 1,058,098 | 4,381,713 | 630,000 | 6,776,249 |
| 3 | Astria Therapeutics | 2024 | Jill Milne | 637,868 | 0 | 5,637,078 | 318,934 | 6,604,416 |
| 4 | Savara, Inc. | 2025 | Matthew Pauls | 660,000 | 3,870,000 | 0 | 297,000 | 4,845,000 |
| 5 | Ocugen, Inc. | 2025 | Shankar Musunuri | 757,900 | 2,194,445 | 1,385,871 | 0 | 4,841,822 |
| 6 | Annexon Biosciences | 2025 | Douglas Love | 670,833 | 0 | 2,522,260 | 371,250 | 3,579,202 |
| 7 | Larimar Therapeutics, Inc. | 2025 | Carole Ben-Maimon | 650,000 | 660,860 | 1,889,160 | 0 | 3,526,423 |
| 8 | Vigil Neuroscience, Inc. | 2024 | Ivana Magovčević-Liebisch | 620,000 | 0 | 1,692,871 | 306,900 | 2,633,571 |
| 9 | Werewolf Therapeutics, Inc. | 2024 | Daniel Hicklin | 608,237 | 0 | 1,559,867 | 0 | 2,545,599 |
| 10 | Inozyme Pharma, Inc. | 2024 | Douglas Treco | 541,667 | 0 | 1,933,375 | 0 | 2,485,392 |
| 11 | Foghorn Therapeutics, Inc. | 2025 | Adrian Gottschalk | 638,000 | 0 | 1,334,037 | 385,990 | 2,361,027 |
| 12 | Adicet Bio, Inc. | 2025 | Chen Schor | 646,294 | 0 | 512,079 | 284,592 | 1,465,747 |
| 13 | Cue Biopharma, Inc. | 2025 | Usman Azam | 143,077 | 0 | 1,042,313 | 0 | 1,185,639 |
| 14 | Rallybio | 2024 | Stephen Uden | 551,200 | 0 | 314,626 | 248,040 | 1,127,666 |
| — | Third Harmonic Bio | — | — | — | — | — | — | not in coverage universe |
Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Incentive design against the same peers
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| Astria Therapeutics | not disclosed | Option 100 | not disclosed | Aon |
| Adicet Bio, Inc. | not disclosed | not disclosed | not disclosed | Aon Consulting, Inc. |
| Annexon Biosciences | 100% of target% | not disclosed | not disclosed | Alpine Rewards |
| Cue Biopharma, Inc. | not disclosed | Option 100 | not disclosed | Radford, an AON Hewitt company |
| Edgewise Therapeutics, Inc. | not disclosed | not disclosed | not disclosed | Alpine |
| Foghorn Therapeutics, Inc. | not disclosed | Options 100 | not disclosed | Pay Governance, LLC |
| Inozyme Pharma, Inc. | not disclosed | not disclosed | not disclosed | Alpine Rewards |
| Larimar Therapeutics, Inc. | not disclosed | Option 75 · RSU 25 | No | Aon |
| Ocugen, Inc. | not disclosed | not disclosed | not disclosed | Pearl Meyer & Partners LLC |
| Rallybio | not disclosed | Option 100 | not disclosed | not disclosed |
| Savara, Inc. | 90% | RSU 100 | not disclosed | Aon |
| Third Harmonic Bio | not disclosed | not disclosed | not disclosed | not disclosed |
| Vigil Neuroscience, Inc. | not disclosed | Option 100 | not disclosed | Aon |
| Viridian Therapeutics, Inc. | 150% | Options 75 · RSU 25 | not disclosed | Compensia |
| Werewolf Therapeutics, Inc. | not disclosed | Option 100 | not disclosed | Pearl Meyer & Partners, LLC |
Read from each company’s Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company’s filing does not state the item.
Say-on-pay history and pay ratio
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2025 | 2025-06-11 | 43,538,692 | 6,611,451 | 5,139 | 86.82% | Passed |
| 2024 | 2024-06-05 | 40,882,888 | 5,346,924 | 6,448 | 88.43% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year’s compensation.
Say-on-pay — history, company’s computation
| Meeting year | Meeting date | Approval — company’s computation |
|---|---|---|
| 2025 | 2025-06-11 | 86.82%a |
| 2024 | 2024-06-05 | 88.43%b |
a. Voting standard not stated in the filing.
b. Voting standard not stated in the filing.
Approval percentages are the company’s own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
Insider trades since the proxy
Every insider equity transaction reported on Form 4 after the 2024 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Gregg Lapointe | Director | 2025-06-11 | A | 26,550 | $0 | $0 | Derivative, Class A Common | Form 4 ↗ |
| Sunil Agarwal | Director | 2025-06-11 | A | 26,550 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Hugh Cole | Director | 2025-06-11 | A | 26,550 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jonathan Violin | Director | 2025-06-11 | A | 26,550 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Kenneth Bate | Director | 2025-06-11 | A | 26,550 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Michael Kishbauch | Director | 2025-06-11 | A | 26,550 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Fred Callori | Director | 2025-06-11 | A | 26,550 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Joanne Beck | Director | 2025-06-11 | A | 26,550 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Andrew Komjathy | Chief Commercial Officer | 2026-01-23 | D | 10 | — | — | Common | Form 4 ↗ |
| Andrea Matthews | Chief Business Officer | 2026-01-23 | D | 262,500 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Andrea Matthews | Chief Business Officer | 2026-01-23 | D | 32,812 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Jill C. Milne | Director | 2026-01-23 | D | 4,377 | — | — | Common | Form 4 ↗ |
| Christopher Morabito | Chief Medical Officer | 2026-01-23 | D | 262,500 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Kenneth Bate | Director | 2026-01-23 | D | 16,666 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Joanne Beck | Director | 2026-01-23 | D | 16,666 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Michael Kishbauch | Director | 2026-01-23 | D | 14,100 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Michael Kishbauch | Director | 2026-01-23 | D | 16,666 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Gregg Lapointe | Director | 2026-01-23 | D | 26,550 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Joanne Beck | Director | 2026-01-23 | D | 14,100 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Joanne Beck | Director | 2026-01-23 | D | 26,550 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Joanne Beck | Director | 2026-01-23 | D | 8,333 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Noah Clauser | Chief Financial Officer | 2026-01-23 | D | 262,500 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Noah Clauser | Chief Financial Officer | 2026-01-23 | D | 55,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Andrew Komjathy | Chief Commercial Officer | 2026-01-23 | D | 225,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Andrew Komjathy | Chief Commercial Officer | 2026-01-23 | D | 55,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Andrew Komjathy | Chief Commercial Officer | 2026-01-23 | D | 45 | — | — | Common, indirect | Form 4 ↗ |
| Gregg Lapointe | Director | 2026-01-23 | D | 14,100 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Gregg Lapointe | Director | 2026-01-23 | D | 14,100 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Gregg Lapointe | Director | 2026-01-23 | D | 8,333 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Gregg Lapointe | Director | 2026-01-23 | D | 16,666 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Andrea Matthews | Chief Business Officer | 2026-01-23 | D | 20,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Jill C. Milne | Director | 2026-01-23 | D | 761,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Jill C. Milne | Director | 2026-01-23 | D | 195,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Christopher Morabito | Chief Medical Officer | 2026-01-23 | D | 80,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Jonathan Violin | Director | 2026-01-23 | A | 14,100 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Jonathan Violin | Director | 2026-01-23 | A | 14,100 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Jonathan Violin | Director | 2026-01-23 | A | 8,333 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Jonathan Violin | Director | 2026-01-23 | A | 14,166 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Jonathan Violin | Director | 2026-01-23 | D | 263,321 | — | — | Common | Form 4 ↗ |
| Benjamin Harshbarger | Chief Legal Officer | 2026-01-23 | D | 262,500 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Hugh Cole | Director | 2026-01-23 | D | 8,333 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Andrew Komjathy | Chief Commercial Officer | 2026-01-23 | D | 45 | — | — | Common, indirect | Form 4 ↗ |
| Joanne Beck | Director | 2026-01-23 | D | 14,100 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Hugh Cole | Director | 2026-01-23 | D | 14,100 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Hugh Cole | Director | 2026-01-23 | D | 14,100 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Hugh Cole | Director | 2026-01-23 | D | 26,550 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Fred Callori | Director | 2026-01-23 | D | 14,100 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Fred Callori | Director | 2026-01-23 | D | 26,550 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Fred Callori | Director | 2026-01-23 | D | 14,100 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Kenneth Bate | Director | 2026-01-23 | D | 26,550 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Kenneth Bate | Director | 2026-01-23 | D | 14,100 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Kenneth Bate | Director | 2026-01-23 | D | 8,333 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Kenneth Bate | Director | 2026-01-23 | D | 14,100 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Michael Kishbauch | Director | 2026-01-23 | D | 26,550 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Michael Kishbauch | Director | 2026-01-23 | D | 14,100 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Sunil Agarwal | Director | 2026-01-23 | D | 26,550 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Sunil Agarwal | Director | 2026-01-23 | D | 28,200 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Jonathan Violin | Director | 2026-01-23 | A | 26,550 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Benjamin Harshbarger | Chief Legal Officer | 2026-01-23 | D | 55,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Benjamin Harshbarger | Chief Legal Officer | 2026-01-23 | D | 33,333 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Michael Kishbauch | Director | 2026-01-23 | D | 8,333 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Hugh Cole | Director | 2026-01-23 | D | 16,666 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Fred Callori | Director | 2026-01-23 | D | 8,333 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Fred Callori | Director | 2026-01-23 | D | 14,166 | — | — | Derivative, Class A Common | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
Sources (95 citations)
Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.
- Section 01, Jill Milne. DEF 14A, filed 2025-04-28. Section “Executive Compensation” · page 24. As printed: 6,604,416. View filing ↗
- Section 01, Christopher Morabito. DEF 14A, filed 2025-04-28. Section “Executive Compensation”. As printed: 2,480,716. View filing ↗
- Section 01, Benjamin Harshbarger. DEF 14A, filed 2025-04-28. Section “Executive Compensation”. As printed: 2,447,933. View filing ↗
- Section 08, Sunil Agarwal. DEF 14A, filed 2025-04-28. Section “Director Compensation”. As printed: 256,282. View filing ↗
- Section 08, Kenneth Bate. DEF 14A, filed 2025-04-28. Section “Director Compensation”. As printed: 177,480. View filing ↗
- Section 08, Gregg Lapointe. DEF 14A, filed 2025-04-28. Section “Director Compensation”. As printed: 146,980. View filing ↗
- Section 08, Jonathan Violin. DEF 14A, filed 2025-04-28. Section “Director Compensation”. As printed: 141,980. View filing ↗
- Section 08, Michael Kishbauch. DEF 14A, filed 2025-04-28. Section “Director Compensation”. As printed: 140,980. View filing ↗
- Section 08, Joanne Beck. DEF 14A, filed 2025-04-28. Section “Director Compensation”. As printed: 139,480. View filing ↗
- Section 08, Fred Callori. DEF 14A, filed 2025-04-28. Section “Director Compensation”. As printed: 135,980. View filing ↗
- Section 08, Hugh Cole. DEF 14A, filed 2025-04-28. Section “Director Compensation”. As printed: 135,730. View filing ↗
- Section 08, Jill C. Milne. DEF 14A, filed 2025-04-28. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 02, Gregg Lapointe 2025-06-11. Form 4, filed 2025-06-12. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Sunil Agarwal 2025-06-11. Form 4, filed 2025-06-12. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Hugh Cole 2025-06-11. Form 4, filed 2025-06-12. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jonathan Violin 2025-06-11. Form 4, filed 2025-06-12. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kenneth Bate 2025-06-11. Form 4, filed 2025-06-12. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael Kishbauch 2025-06-11. Form 4, filed 2025-06-12. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Fred Callori 2025-06-11. Form 4, filed 2025-06-12. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Joanne Beck 2025-06-11. Form 4, filed 2025-06-12. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Andrew Komjathy 2026-01-23. Form 4, filed 2026-01-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Andrea Matthews 2026-01-23. Form 4, filed 2026-01-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Andrea Matthews 2026-01-23. Form 4, filed 2026-01-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jill C. Milne 2026-01-23. Form 4, filed 2026-01-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Christopher Morabito 2026-01-23. Form 4, filed 2026-01-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kenneth Bate 2026-01-23. Form 4, filed 2026-01-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Joanne Beck 2026-01-23. Form 4, filed 2026-01-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael Kishbauch 2026-01-23. Form 4, filed 2026-01-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael Kishbauch 2026-01-23. Form 4, filed 2026-01-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Gregg Lapointe 2026-01-23. Form 4, filed 2026-01-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Joanne Beck 2026-01-23. Form 4, filed 2026-01-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Joanne Beck 2026-01-23. Form 4, filed 2026-01-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Joanne Beck 2026-01-23. Form 4, filed 2026-01-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Noah Clauser 2026-01-23. Form 4, filed 2026-01-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Noah Clauser 2026-01-23. Form 4, filed 2026-01-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Andrew Komjathy 2026-01-23. Form 4, filed 2026-01-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Andrew Komjathy 2026-01-23. Form 4, filed 2026-01-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Andrew Komjathy 2026-01-23. Form 4, filed 2026-01-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Gregg Lapointe 2026-01-23. Form 4, filed 2026-01-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Gregg Lapointe 2026-01-23. Form 4, filed 2026-01-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Gregg Lapointe 2026-01-23. Form 4, filed 2026-01-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Gregg Lapointe 2026-01-23. Form 4, filed 2026-01-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Andrea Matthews 2026-01-23. Form 4, filed 2026-01-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jill C. Milne 2026-01-23. Form 4, filed 2026-01-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jill C. Milne 2026-01-23. Form 4, filed 2026-01-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Christopher Morabito 2026-01-23. Form 4, filed 2026-01-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jonathan Violin 2026-01-23. Form 4, filed 2026-01-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jonathan Violin 2026-01-23. Form 4, filed 2026-01-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jonathan Violin 2026-01-23. Form 4, filed 2026-01-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jonathan Violin 2026-01-23. Form 4, filed 2026-01-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jonathan Violin 2026-01-23. Form 4, filed 2026-01-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Benjamin Harshbarger 2026-01-23. Form 4, filed 2026-01-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Hugh Cole 2026-01-23. Form 4, filed 2026-01-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Andrew Komjathy 2026-01-23. Form 4, filed 2026-01-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Joanne Beck 2026-01-23. Form 4, filed 2026-01-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Hugh Cole 2026-01-23. Form 4, filed 2026-01-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Hugh Cole 2026-01-23. Form 4, filed 2026-01-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Hugh Cole 2026-01-23. Form 4, filed 2026-01-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Fred Callori 2026-01-23. Form 4, filed 2026-01-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Fred Callori 2026-01-23. Form 4, filed 2026-01-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Fred Callori 2026-01-23. Form 4, filed 2026-01-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kenneth Bate 2026-01-23. Form 4, filed 2026-01-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kenneth Bate 2026-01-23. Form 4, filed 2026-01-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kenneth Bate 2026-01-23. Form 4, filed 2026-01-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kenneth Bate 2026-01-23. Form 4, filed 2026-01-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael Kishbauch 2026-01-23. Form 4, filed 2026-01-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael Kishbauch 2026-01-23. Form 4, filed 2026-01-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Sunil Agarwal 2026-01-23. Form 4, filed 2026-01-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Sunil Agarwal 2026-01-23. Form 4, filed 2026-01-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jonathan Violin 2026-01-23. Form 4, filed 2026-01-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Benjamin Harshbarger 2026-01-23. Form 4, filed 2026-01-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Benjamin Harshbarger 2026-01-23. Form 4, filed 2026-01-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael Kishbauch 2026-01-23. Form 4, filed 2026-01-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Hugh Cole 2026-01-23. Form 4, filed 2026-01-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Fred Callori 2026-01-23. Form 4, filed 2026-01-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Fred Callori 2026-01-23. Form 4, filed 2026-01-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 06, 2025 vote. Form 8-K, filed 2025-06-12. Item 5.07 · say-on-pay result. As reported: 86.82% (votes for as printed: 43,538,692). View filing ↗
- Section 06, 2024 vote. Form 8-K, filed 2024-06-06. Item 5.07 · say-on-pay result. As reported: 88.43% (votes for as printed: 40,882,888). View filing ↗
- Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
- Section 09b board cost (computed). Computed. Cash 444,723 + equity 0 + all other 0 = 444,723, summed across the director compensation table rows.
- Edgewise Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-23. CEO total compensation as printed in Edgewise Therapeutics, Inc.'s own proxy. As printed: 7,359,546. View filing ↗
- Viridian Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-17. CEO total compensation as printed in Viridian Therapeutics, Inc.'s own proxy. As printed: 6,776,249. View filing ↗
- Astria Therapeutics (subject), Section 10b CEO total. DEF 14A, filed 2025-04-28. CEO total compensation as printed in Astria Therapeutics's own proxy. As printed: 6,604,416. View filing ↗
- Savara, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-24. CEO total compensation as printed in Savara, Inc.'s own proxy. As printed: 4,845,000. View filing ↗
- Ocugen, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-28. CEO total compensation as printed in Ocugen, Inc.'s own proxy. As printed: 4,841,822. View filing ↗
- Annexon Biosciences, Section 10b CEO total. DEF 14A, filed 2026-04-27. CEO total compensation as printed in Annexon Biosciences's own proxy. As printed: 3,579,202. View filing ↗
- Larimar Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-20. CEO total compensation as printed in Larimar Therapeutics, Inc.'s own proxy. As printed: 3,526,423. View filing ↗
- Vigil Neuroscience, Inc., Section 10b CEO total. DEF 14A, filed 2025-03-31. CEO total compensation as printed in Vigil Neuroscience, Inc.'s own proxy. As printed: 2,633,571. View filing ↗
- Werewolf Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2025-04-28. CEO total compensation as printed in Werewolf Therapeutics, Inc.'s own proxy. As printed: 2,545,599. View filing ↗
- Inozyme Pharma, Inc., Section 10b CEO total. DEF 14A, filed 2025-04-29. CEO total compensation as printed in Inozyme Pharma, Inc.'s own proxy. As printed: 2,485,392. View filing ↗
- Foghorn Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-30. CEO total compensation as printed in Foghorn Therapeutics, Inc.'s own proxy. As printed: 2,361,027. View filing ↗
- Adicet Bio, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-29. CEO total compensation as printed in Adicet Bio, Inc.'s own proxy. As printed: 1,465,747. View filing ↗
- Cue Biopharma, Inc., Section 10b CEO total. DEF 14A, filed 2026-03-16. CEO total compensation as printed in Cue Biopharma, Inc.'s own proxy. As printed: 1,185,639. View filing ↗
- Rallybio, Section 10b CEO total. DEF 14A, filed 2025-04-07. CEO total compensation as printed in Rallybio's own proxy. As printed: 1,127,666. View filing ↗
- Section 10a, Savara, Inc. reciprocity. DEF 14A. Savara, Inc. names Astria Therapeutics in its own disclosed peer group (read from its most recent proxy). View filing ↗